We report a retrospective analysis of 110 unselected pediatric patients with acute lymphoblastic leukemia (ALL) treated during 2015–2017 in a charity-funded public institution in Cambodia with a reduced intensity ALL-Moscow Berlin (MB)-91 protocol. No patient abandoned treatment. Sixty-three patients (57%) were high risk (HR). Seventy-two patients (65.5%) reached complete remission (CR) on day 36. The 3-year event-free survival (EFS) and overall survival (OS) was 34.9% (50.5% for standard risk [SR]). Most deaths resulted from infections (40 [53.3%]) and bleeding (15 [20%]). With further selective reduction of treatment intensity and access to platelet infusion, leukemia therapy is justified in this setting.

中文翻译：

---

柬埔寨儿童急性淋巴细胞白血病的治疗

我们报告了一项回顾性分析，对 2015-2017 年期间在柬埔寨一家慈善资助的公共机构接受治疗的 110 名未选择的急性淋巴细胞白血病 (ALL) 儿科患者采用降低强度的 ALL-莫斯科柏林 (MB)-91 方案进行治疗。没有患者放弃治疗。63 名患者 (57%) 为高危 (HR)。72 名患者 (65.5%) 在第 36 天达到完全缓解 (CR)。3 年无事件生存 (EFS) 和总生存 (OS) 为 34.9%（标准风险 [SR] 为 50.5%）。大多数死亡是由感染（40 [53.3%]）和出血（15 [20%]）引起的。随着治疗强度的进一步选择性降低和血小板输注的获得，白血病治疗在这种情况下是合理的。